Canadian association of neurosciences review: Polyglutamine expansion neurodegenerative diseases

Canadian Journal of Neurological Sciences

Volumn 33, Issue 3, 2006, Pages 278-291

  Truant, Ray ^a   Raymond, Lynn A ^b   Xia, Jianrun ^a   Pinchev, Deborah ^a   Burtnik, Anjee ^a   Atwal, Randy Singh ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ATAXIN 1; ATAXIN 7; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IMATINIB; POLYGLUTAMINE; PROTEASOME; PROTEIN TYROSINE KINASE INHIBITOR; REPETITIVE DNA;

DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; GENETIC DISORDER; GENETIC MODEL; HUMAN; HUNTINGTON CHOREA; INCIDENCE; KENNEDY DISEASE; MACHADO JOSEPH DISEASE; MOLECULAR BIOLOGY; NEUROLOGIC DISEASE; NEUROSCIENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 33748475640     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710000514X     Document Type: Review

References (193)

1. Schalling M, Hudson TJ, Buetow KH, Housman DE. Direct detection of novel expanded trinucleotide repeats in the human genome. Nat Genet. 1993; 4(2): 135-9.
2. Epplen C, Epplen J T. Expression of (cac)n/(gtg)n simple repetitive sequences in mRNA of human lymphocytes. Hum Genet. 1994; 93(1): 35-41.
3. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991; 352(6330): 77-9.
4. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993; 72(6): 971-83.
5. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994; 8(3): 221-8.
6. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Jr, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993; 4(3): 221-6.
7. Behn-Krappa A, Doerfler W. Enzymatic amplification of synthetic oligodeoxyribonucleotides: implications for triplet repeat expansions in the human genome. Hum Mutat. 1994; 3(1): 19-24.
8. Chong SS, McCall AE, Cota J, Subramony SH, Orr HT, Hughes MR, et al. Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1995; 10(3): 344-50.
9. Cancel G, Abbas N, Stevanin G, Durr A, Chneiweiss H, Neri C, et al. Marked phenotypic heterogeneity associated with expansion of a CAG repeat sequence at the spinocerebellar ataxia 3/Machado-Joseph disease locus. Am J Hum Genet. 1995; 57(4): 809-16.
10. Trottier Y, Biancalana V, Mandel J L. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet. 1994; 31(5): 377-82.
11. Djousse L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, Ross CA, et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4pl6. Neurogenetics. 2004; 5(2): 109-14.
12. Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet. 2003; 73(3): 682-7.
13. Ashizawa T, Dunne PW, Ward PA, Seltzer WK, Richards CS, Effects of the sex of myotonic dystrophy patients on the unstable triplet repeat in their affected offspring. Neurology. 1994; 44(1): 120-2.
14. Housman D, Gain of glutamines, gain of function? Nat Genet. 1995; 10(1): 3-4.
15. Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, et al. A one-hit model of cell death in inherited neuronal degenerations. Nature. 2000; 406(6792): 195-9.
16. Benjamin CM, Lashwood A. United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington's disease. Clin Genet. 2000; 58(1): 41-9.
17. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65(4): 267-77.
18. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996; 87(3): 493-506.
19. Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci. 2004; 24(40): 8853-61.
20. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron. 2003; 38(3): 375-87.
21. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998; 95(1): 41-53.
22. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 1995; 82(6): 937-48.
23. Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci USA. 2000; 97(12): 6739-44.
24. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA. 2005; 102(3): 892-7.
25. Perutz MF, Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr Opin Struct Biol. 1996; 6(6): 848-58.
26. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997; 90(3): 537-48.
27. Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li X J, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet, 2000; 9(4): 503-13.
28. Xia J, Lee D H, Taylor J, Vandelft M, Truant R. Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet. 2003; 12(12): 1393-403.
29. Muchowski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron. 2002; 35(1): 9-12.
30. Poirier MA, Jiang H, Ross CA. A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet. 2005; 14(6): 765-74.
31. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998; 18(2): 164-7.
32. Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tome FM, Oculopharyngeal muscular dystrophy. Semin Neurol. 1999; 19(1): 59-66.
33. Utsch B, Becker K, Brock D, Lentze MJ, Bidlingmaier F, Ludwig M. A novel stable polyalanine [poly(A)] expansion in the HOXA13 gene associated with hand-foot-genital syndrome: proper function of poly(A)-harbouring transcription factors depends on a critical repeat length? Hum Genet. 2002; 110(5): 488-94.
34. De Baere E, Beysen D, Oley C, Lorenz B, Cocquet J, De Sutter P, et al. FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet. 2003; 72(2): 478-87.
35. Kremer HP, Kremer GH. Demise of a neuronal population in Huntington's disease and the importance of hyponeuronogenesis. Clin Neurol Neurosurg. 1992; 94 Suppl: S7-8.
36. Hayden MR, Huntington's chorea. 1981, Berlin; New York: Springer-Verlag, xvii. 192.
37. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985; 44(6): 559-77.
38. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol. 1997; 42(4): 604-12.
39. Raymond LA G, A. Huntington's disease: Targeting the triad. Canadian Journal of Diagnosis. 2005; April: 82-7.
40. Maruyama H, Kawakami H, Nakamura S. Reevaluation of the exact CAG repeat length in hereditary cerebellar ataxias using highly denaturing conditions and long PCR. Hum Genet. 1996; 97(5): 591-5.
41. Norremolle A, Riess O, Epplen JT, Fenger K, Hasholt L, Sorensen SA. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet. 1993; 2(9): 1475-6.
42. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 1995; 378(6555): 403-6.
43. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, Tait D, et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet. 1997; 6(3): 487-95.
44. Li XJ, Li SH, Sharp AH, Nucifora FC, Jr., Schilling G, Lanahan A, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 1995; 378(6555): 398-402.
45. Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet. 1998; 7(9): 1463-74.
46. Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, et al. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet. 2000; 9(14): 2175-82.
47. Block-Galarza J, Chase KO, Sapp E, Vaughn KT, Vallee RB, DiFiglia M, et al. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport. 1997; 8(9-10): 2247-51.
48. McPherson PS. The endocytic machinery at an interface with the actin cytoskeleton: a dynamic, hip intersection. Trends Cell Biol. 2002; 12(7): 312-5.
49. Ferner V. Hip, hip, hippi! Nat Cell Biol. 2002; 4(2): E30.
50. Lee SJ, Choi JY, Sung YM, Park H, Rhim H, Kang S. E3 ligase activity of RING finger proteins that interact with Hip-2, a human ubiquitin-conjugating enzyme. FEBS Lett. 2001; 503(1): 61-4.
51. Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, et al. The Gin-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A. 2001; 98(4): 1811-6.
52. McMahon HT, Mills IG. COP and clathrin-coated vesicle budding: different pathways, common approaches. Curr Opin Cell Biol. 2004; 16(4): 379-91.
53. Wu LG. Kinetic regulation of vesicle endocytosis at synapses. Trends Neurosci. 2004; 27(9): 548-54.
54. Rohrbough J, Broadie K. Lipid regulation of the synaptic vesicle cycle. Nat Rev Neurosci. 2005; 6(2): 139-50.
55. Phelps MA, Foraker AB, Swaan PW. Cytoskeletal motors and cargo in membrane trafficking: opportunities for high specificity in drug intervention. Drug Discov Today. 2003; 8(11): 494-502.
56. Dell KR. Dynactin polices two-way organelle traffic. J Cell Biol. 2003; 160(3): 291-3.
57. Pal A, Severin F, Lommer B, Shevchenko A, Zerial M. Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease. J Cell Biol. 2006; 172(4): 605-18.
58. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 1995; 14(5): 1075-81.
59. De Rooij KE, Dorsman JC, Smoor MA, Den Dunnen JT, Van Ommen GJ. Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum Mol Genet. 1996; 5(8): 1093-9.
60. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003; 35(1): 76-83.
61. Cattaneo E, Rigamonti D, Zuccato C, The enigma of Huntington's disease. Sci Am. 2002; 287(6): 92-7.
62. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001; 293(5529): 493-8.
63. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem. 2000; 75(5): 2190-9.
64. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther. 1999; 10(18): 2987-97.
65. Nucifora FC, Jr, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, et al. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem. 2003; 278(15): 13047-55.
66. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu Y Z, Gohler H, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA. 2000; 97(12): 6763-8.
67. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004; 118(1): 127-38.
68. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet. 1995; 11(2): 155-63.
69. Rosen A. Huntingtin: new marker along the road to death? Nat Genet. 1996; 13(4): 380-2.
70. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998; 273(15): 9158-67.
71. Tobin AJ, Signer ER. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000; 10(12): 531-6.
72. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther. 2004; 9(5): 682-8.
73. Hillson JL, Furst DE. Rofecoxib. Expert Opin Pharmacother. 2000; 1(5): 1053-66.
74. Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today (Barc). 2004; 40(5): 395-414.
75. Liu S, Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des. 2004; 10(15): 1827-43.
76. Flynn DL, Abood NA, Holwerda BC. Recent advances in antiviral research: identification of inhibitors of the herpesvirus proteases. Curr Opin Chem Biol. 1997; 1(2): 190-6.
77. Wesche H, Xiao SH, Young SW. High throughput screening for protein kinase inhibitors. Comb Chem High Throughput Screen. 2005; 8(2): 181-95.
78. Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet. 2002; 30(4): 367-76.
79. Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci USA. 2002; 99 Suppl 4: S16400-6.
80. Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 2003; 40(4): 685-94.
81. Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA. 2002; 99(2): 1002-7.
82. Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci. 2004; 24(1): 269-81.
83. Wang J, Gines S, MacDonald ME, Gusella JF. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 2005; 6(1): 1.
84. Hoshino M, Tagawa K, Okuda T, Murata M, Oyanagi K, Arai N, et al. Histone deacerylase activity is retained in primary neurons expressing mutant huntingtin protein. J Neurochem. 2003; 87(1): 257-67.
85. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001; 413(6857): 739-43.
86. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacerylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003; 23(28): 9418-27.
87. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, et al. Pharmacologinal promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA. 2006; 103(1): 4246-51.
88. Stockwell BR. Chemical genetic screening approaches to neurobiology. Neuron. 2002; 36(4): 559-62.
89. Jelkmann W, Molecular biology of erythropoietin. Intern Med. 2004; 43(8): 649-59.
90. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet. 2004; 364(9438): 985-96.
91. Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr Pharm Des. 2004; 10(28): 3505-24.
92. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P. The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol. 2004; 92(4): 317-25.
93. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol. 2004; 51(1): 55-67.
94. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002; 2(6): 831-7.
95. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem. 2003; 278(50): 50514-22.
96. Kumar U, Asotra K, Patel SC, Patel YC. Expression of NMDA receptor-1 (NR1) and huntingtin in striatal neurons which colocalize somatostatin, neuropeptide Y, and NADPH diaphorase: a double-label histochemical and immunohistochemical study. Exp Neurol. 1997; 145(2 Pt 1): 412-24.
97. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem. 1999; 72(5): 1890-8.
98. Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci. 2001; 17(1): 41-53.
99. Anborgh PH, Godin C, Pampillo M, Dhami GK, Dale LB, Cregan SP, et al. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J Biol Chem. 2005; 280(41): 34840-8.
100. Takano H, Gusella JF. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci. 2002; 3(1): 15.
101. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci. 2004; 24(37): 7999-8008.
102. Garcia M, Charvin D, Caboche J. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience. 2004; 127(4): 859-70.
103. Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004; 322(4): 1310-7.
104. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci USA. 2005; 102(7): 2602-7.
105. Panov AV, Lund S, Greenamyre JT. Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem. 2005; 269(1-2): 143-52.
106. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet. 1997; 15(1): 62-9.
107. Matsuyama Z, Yanagisawa NK, Aoki Y, Black JL 3rd, Lennon VA, Mori Y, et al. Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2+ channel-loss-of-function cellular model of SCA6. Neurobiol Dis. 2004; 17(2): 198-204.
108. Brinkmann AO, Trapman J. Androgen receptor mutants that affect normal growth and development. Cancer Surv. 1992; 14: 95-111.
109. Diamond M, Watson LA. Androgen insensitivity syndrome and Klinefelter's syndrome: sex and gender considerations. Child Adolesc Psychiatr Clin N Am. 2004; 13(3): 623-40, viii.
110. Lingappa VR, Blobel G. Early events in the biosynthesis of secretory and membrane proteins: the signal hypothesis. Recent Prog Horm Res. 1980; 36: 451-75.
111. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem. 2003; 278(43): 41998-2005.
112. Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005; 128(Pt 3): 659-70.
113. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997; 19(2): 333-44.
114. Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol. 2001; 153(2): 283-94.
115. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet. 1999; 8(5): 731-41.
116. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002; 35(5): 843-54.
117. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanaka H, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002; 35(5): 855-64.
118. Katsuno M, Adachi H, Tanaka F, Sobue G. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives. J Mol Med. 2004; 82(5): 298-307.
119. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology. 2004; 40(6): 1361-9.
120. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet. 1997; 17(4): 404-10.
121. Landwehrmeyer GB, McNeil SM, Dure LS 4th, Ge P, Aizawa H, Huang Q, et al. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol. 1995; 37(2): 218-30.
122. Matsuyama N, Hadano S, Onoe K, Osuga H, Showguchi-Miyata J, Gondo Y, et al. Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat. Genomics. 2000; 69(1): 72-85.
123. Orr HT, Zoghbi HY. SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. Hum Mol Genet. 2001; 10(20): 2307-11.
124. Di Donato S. The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias. Ital J Neurol Sci, 1998; 19(6): 335-43.
125. Taroni F, Di Donato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci. 2004; 5(8): 641-55.
126. Silveira I, Lopes-Cendes I, Kish S, Maciel P, Gaspar C, Coutinho P, et al. Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients. Neurology. 1996; 46(1): 214-8.
127. van de Warrenburg BP, Sinke RJ, Verschuuren-Bemelmans CC, Scheffer H, Brunt ER, Ippel PF, et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology. 2002; 58(5): 702-8.
128. Albin RL. Dominant ataxias and Friedreich ataxia: an update. Curr Opin Neurol. 2003; 16(4): 507-14.
129. Schols L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004; 3(5): 291-304.
130. Zoghbi HY, Orr HT, Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000; 23: 217-47.
131. Zoghbi HY, Orr HT. Spinocerebellar ataxia type 1. Semin Cell Biol. 1995; 6(1): 29-35.
132. Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 1997; 91(6): 753-63.
133. Ordway JM, Cearley JA, Detloff PJ. CAG-polyglutamine-repeat mutations: independence from gene context. Philos Trans R Soc Lond B Biol Sci. 1999; 354(1386): 1083-8.
134. Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003; 113(4): 457-68.
135. Kaytor MD, Byam CE, Tousey SK, Stevens SD, Zoghbi HY, Orr HT. A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet. 2005; 14(8): 1095-105.
136. Yue S, Serra HG, Zoghbi HY, Orr HT. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet. 2001; 10(1): 25-30.
137. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, McKeown M, et al. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci USA. 2004; 101(12): 4047-52.
138. Stenoien DL, Mielke M, Mancini MA. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol. 2002; 4(10): 806-10.
139. Irwin S, Vandelft M, Pinchev D, Howell JL, Graczyk J, Orr HT, et al. RNA association and nucleocytoplasmic shuttling by ataxin-1. J Cell Sci. 2005; 118(Pt 1): 233-42.
140. Kim S, Nollen EA, Kitagawa K, Bindokas VP, Morimoto RI. Polyglutamine protein aggregates are dynamic. Nat Cell Biol. 2002; 4(10): 826-31.
141. Koyano S, Uchihara T, Fujigasaki H, Nakamura A, Yagishita S, Iwabuchi K. Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci Lett. 1999; 273(2): 117-20.
142. Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet. 2000; 26(1): 44-50.
143. Shibata H, Huynh DP, Pulst SM. A novel protein with RNA-binding motifs interacts with ataxin-2. Hum Mol Genet. 2000; 9(9): 1303-13.
144. Albrecht M, Golatta M, Wullner U, Lengauer T. Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem. 2004; 271(15): 3155-70.
145. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S. An integrative approach to gain insights into the cellular function of human ataxin-2. J Mol Biol. 2005; 346(1): 203-14.
146. Pinol-Roma S, Dreyfuss G. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature. 1992; 355(6362): 730-2.
147. Jorgensen P, Breitkreutz BJ, Breitkreutz K, Stark C, Liu G, Cook M, et al. Harvesting the genome's bounty: integrative genomics. Cold Spring Harb Symp Quant Biol. 2003; 68: 431-43.
148. Eberhart DE, Malter HE, Feng Y, Warren ST. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996; 5(8): 1083-91.
149. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum S A, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001; 107(4): 477-87.
150. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. CLIP identifies Nova-regulated RNA networks in the brain. Science. 2003; 302(5648): 1212-5.
151. Jun L, Frints S, Duhamel H, Herold A, Abad-Rodrigues J, Dotti C, et al. NXF5, a novel member of the nuclear RNA export factor family, is lost in a male patient with a syndromic form of mental retardation. Curr Biol. 2001; 11(18): 1381-91.
152. Hayes S, Turecki G, Brisebois K, Lopes-Cendes I, Gaspar C, Riess O, et al. CAG repeat length in RAI1 is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2). Hum Mol Genet. 2000; 9(12): 1753-8.
153. Gouw LG, Digre KB, Harris CP, Haines JH, Ptacek LJ. Autosomal dominant cerebellar ataxia with retinal degeneration: clinical, neuropathologic, and genetic analysis of a large kindred. Neurology. 1994; 44(8): 1441-7.
154. Kaytor MD, Duvick LA, Skinner PJ, Koob MD, Ranum LP, Orr HT. Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. Hum Mol Genet. 1999; 8(9): 1657-64.
155. Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, Chen S, et al. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron. 2003; 37(3): 383-401.
156. Grote SK, La Spada AR. Insights into the molecular basis of polyglutamine neurodegeneration from studies of a spinocerebellar ataxia type 7 mouse model. Cytogenet Genome Res. 2003; 100(1-4): 164-74.
157. Chen S, Peng GH, Wang X, Smith AC, Grote SK, Sopher BL, et al. Interference of Crx-dependent transcription by ataxin-7 involves interaction between the glutamine regions and requires the ataxin-7 carboxy-terminal region for nuclear localization. Hum Mol Genet. 2004; 13(1): 53-67.
158. Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet. 2004; 13(12): 1257-65.
159. Taylor J, Grote SK, Xia J, Vandelft M, Graczyk J, Ellerby LM, et al. Ataxin-7 can export from the nucleus via a conserved exportin-dependent signal. J Biol Chem. 2006; 281(5): 2730-9.
160. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet. 2005; 14(5): 679-91.
161. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004; 431(7010): 805-10.
162. Mushegian AR, Vishnivetskiy SA, Gurevich VV. Conserved phosphoprotein interaction motif is functionally interchangeable between ataxin-7 and arrestins. Biochemistry. 2000; 39(23): 6809-13.
163. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science, 2005; 308(5721): 512-7.
164. La Spada AR, Paulson HL, Fischbeck KH. Trinucleotide repeat expansion in neurological disease. Ann Neurol. 1994; 36(6): 814-22.
165. Bruni AC, Takahashi-Fujigasaki J, Maltecca F, Foncin JF, Servadio A, Casari G, et al. Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol. 2004; 61(8): 1314-20.
166. Perez MK, Paulson HL, Pendse SJ, Saionz SJ, Bonini NM, Pittman RN. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol. 1998; 143(6): 1457-70.
167. Gunther P, Storch A, Schwarz J, Sabri O, Steinbach P, Wagner A, et al. Basal ganglia involvement of a patient with SCA 17-a new form of autosomal dominant spinocerebellar ataxia. J Neurol. 2004; 251(7): 896-7.
168. Hagenah JM, Zuhlke C, Hellenbroich Y, Heide W, Klein C. Focal dystonia as a presenting sign of spinocerebellar ataxia 17. Mov Disord. 2004; 19(2): 217-20.
169. Ichikawa Y, Goto J, Hattori M, Toyoda A, Ishii K, Jeong SY, et al. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet. 2001; 46(7): 413-22.
170. Gaspar C, Lopes-Cendes I, Hayes S, Goto J, Arvidsson K, Dias A, et al. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am J Hum Genet. 2001; 68(2): 523-8.
171. Durr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol. 1996; 39(4): 490-9.
172. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell. 2005; 17(3): 351-65.
173. Park Y, Hong S, Kim S J, Kang S. Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Mol Cells. 2005; 19(1): 23-30.
174. Burnett BG, Pittman RN. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci USA. 2005; 102(12): 4330-5.
175. Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haiem L, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci. 2004; 24(45): 10266-79.
176. Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998; 8(4): 669-79.
177. Chai Y, Shao J, Miller VM, Williams A, Paulson HL. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA. 2002; 99(14): 9310-5.
178. Gaspar C, Jannatipour M, Dion P, Laganiere J, Sequeiros J, Brais B, et al. CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum Mol Genet. 2000; 9(13): 1957-66.
179. Silveira I, Manaia A, Melki J, Magarino C, Lunkes A, Hernandez A, et al. Machado-Joseph disease is genetically different from Holguin dominant ataxia (SCA2). Genomics. 1993; 17(3): 556-9.
180. Velazquez-Perez L, Garcia R, Santos FN, Paneque HM, Medina HE, Hechavarria PR. [Hereditary ataxias in Cuba. Historical, epidemiological, clinical, electrophysiological and quantitative neurological features]. Rev Neurol, 2001; 32(1): 71-6.
181. Komure O, Sano A, Nishino N, Yamauchi N, Ueno S, Kondoh K, et al. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology. 1995; 45(1): 143-9.
182. Yazawa I, Hazeki N, Kanazawa I. Different complex formations of dentatorubral-pallidoluysian atrophy (DRPLA) protein in human and rat neurons. Biochem Biophys Res Commun. 1998; 253(2): 209-13.
183. Yazawa I. Aberrant phosphorylation of dentatorubral-pallidoluysian atrophy (DRPLA) protein complex in brain tissue. Biochem J. 2000; 351 Pt 3: 587-93.
184. Schilling G, Wood JD, Duan K, Slunt HH, Gonzales V, Yamada M, et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron. 1999; 24(1): 275-86.
185. Nucifora FC, Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 2001; 291(5512): 2423-8.
186. Truant R. Nucleocytplasmic Shuttling of Huntingtin and Huntington's Disease. Clin. Neuro. Res. 2003; 3: 157-164.
187. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 2000; 101(1): 57-66.
188. Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J, Lucas JJ. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci. 2001; 21(22): 8772-81.
189. Caplen NJ. RNAi quashes polyQ. Nat Med. 2004; 10(8): 775-6.
190. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004; 10(8): 816-20.
191. Li Y, Yokota T, Matsumura R, Taira K, Mizusawa H. Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA. Ann Neurol. 2004; 56(1): 124-9.
192. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene. 2003; 22(36): 5712-5.
193. Azzouz M, Kingsman SM, Mazarakis ND. Lentiviral vectors for treating and modeling human CNS disorders. J Gene Med. 2004; 6(9): 951-62.